Summary & Overview
Cesarean Section without Sterilization with MCC: Inpatient Reimbursement Overview
DRG 786 pertains to Cesarean Section without Sterilization with Major Complication or Comorbidity and encompasses cesarean deliveries complicated by significant maternal or fetal conditions that increase resource needs. It matters for inpatient reimbursement because assignment to this Diagnosis-Related Group raises payment relative to lower-severity cesarean groupings, reflecting higher expected costs and hospital resource utilization.
DRG 786 Overview
DRG 786 covers inpatient admissions for Cesarean Section without Sterilization when a Major Complication or Comorbidity is present, reflecting higher clinical severity than standard cesarean cases. This category captures patients with significant maternal or fetal conditions that drive greater resource use, longer lengths of stay, and increased costs. As a Medicare inpatient reimbursement grouping, it affects payment classification, hospital billing, and prospective payment system case mix calculations. Accurate coding of diagnoses and procedures that justify the Major Complication or Comorbidity is essential for appropriate assignment to this Diagnosis-Related Group.
Clinical Trials
- Acute perioperative management trials: randomized or controlled studies evaluating protocols to reduce intraoperative and immediate postoperative complications in cesarean deliveries complicated by major comorbidity (eg, severe preeclampsia, significant hemorrhage risk, or severe cardiac disease). These trials enroll pregnant patients undergoing cesarean section who have an identified major complication or comorbidity (the MCC component) and test anesthesia strategies, blood-conservation techniques, rapid hemorrhage control bundles, or enhanced monitoring approaches to reduce ICU transfers and severe morbidity. Results are directly relevant to hospital providers and payers because reducing perioperative complications can shorten length of stay, lower resource-intensive interventions (eg, transfusions, reoperations, critical care), and improve DRG-related cost and quality metrics.
- Comparative effectiveness studies of obstetric surgical and anesthetic techniques: observational cohort studies or pragmatic randomized trials comparing different surgical approaches (eg, standard cesarean technique vs modified approaches for placenta accreta spectrum or other high-risk indications) or anesthetic regimens in patients with major complications. These studies focus on pregnant patients with conditions that drive the MCC designation—such as placenta previa with suspected accreta, severe hypertensive disorders, or major coagulopathy—and assess outcomes like intraoperative blood loss, maternal morbidity, neonatal outcomes, and need for additional procedures. Understanding which techniques yield better clinical outcomes and lower complication rates helps clinicians optimize care pathways and helps payers and hospitals identify best practices that may reduce costly downstream interventions and readmissions.
- Post-discharge outcomes and health services research: prospective cohort or registry-based studies tracking longer-term maternal health, readmissions, postpartum complications (eg, wound infection, thromboembolism), mental health, and neonatal care needs after a cesarean with major complications. These studies enroll the higher-risk population discharged after a complicated cesarean and evaluate drivers of readmission, outpatient resource utilization, and maternal functional recovery, often including equity analyses across sociodemographic groups. Findings inform discharge planning, ambulatory follow-up protocols, and care coordination strategies important to providers aiming to improve outcomes and to payers interested in reducing readmission rates and total episode-of-care costs associated with this DRG.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.